AllergyTalk Episode 52 - Is Treatment Refractory Wheezing a Sign of a Silent Viral infection?
Price: FREE for members and non-members
Recorded 4/29/2025
AllergyWatch issue Jan/Feb 2025
Speakers: Gerald Lee, MD, FACAAI; Stanley Fineman, MD, FACAAI; and Sarah Spriet, DO, FACAAI
Listeners can earn credit by completing the posttest questions
AllergyTalk is a podcast designed to provide easy access to research summaries from Allergy Watch and recommendations from subject matter experts in order to bring physicians up to date onthe latest advances in the field of allergy and immunology.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Primary Care Providers
Fellows-in-Training
Learning Objectives
Upon completion of this podcast, the participant should be able to:
1. Summarize recent key developments in the field of allergy and immunology, and assess how these findings impact clinical practice in allergy/immunology management.
2. Demonstrate practical strategies for implementing current recommendations for allergy and immunology conditions, including specific tools and techniques that can be easily integrated into daily clinical workflows.
3. Evaluate the effectiveness of therapy implementation in their practice and employ strategies to monitor patient outcomes in accordance with the most current allergy and immunology guidelines.
Articles reviewed in this episode:
- Silent Rhinovirus Infection May Underly Treatment-Refractory Wheezing
- Moderate and Vigorous Exercise Improve Asthma Outcomes in Adults
- A Novel Role for Neutrophils in Allergic Asthma
All relevant financial relationships with ineligible companies have been mitigated.
Gerald Lee, MD
No relevant financial relationships with ineligible companies to disclose
Stanley Fineman, MD
Researcher: Novartis, Aimmune, DBV
Speaker: Genentech
Sarah Spriet, DO
No relevant financial relationships with ineligible companies to disclose
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Attendance